Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05039281 · ClinicalTrials.gov registry record · Phase 1

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

A Phase 1 study of Recurrent Glioblastoma and Recurrent Gliosarcoma, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
6
Enrollment target
1
Study location

NCT05039281: Recruiting Phase 1 study of Recurrent Glioblastoma and Recurrent Gliosarcoma, sponsored by M.D. Anderson Cancer Center.

NCT05039281 is a Phase 1 study of Recurrent Glioblastoma and Recurrent Gliosarcoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 6 participants, below the 69-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05039281, a Phase 1 study of Recurrent Glioblastoma and Recurrent Gliosarcoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
6 participants
Enrollment target
1
Study location

Study Summary

This phase I/II trial tests the safety and side effects of atezolizumab in combination with cabozantinib and whether they work to shrink tumors in patients with glioblastoma that has come back (recurrent). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab and cabozantinib may help control the disease in patients with recurrent glioblastoma.

Primary Outcome

Will estimate the 6 months PFS distribution using the Kaplan-Meier method.

Conditions Studied

Recurrent Glioblastoma Recurrent Gliosarcoma

Interventions

  • BIOLOGICAL Atezolizumab
  • DRUG Cabozantinib

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2022-09-23
Est. Completion 2027-12-31
Phase Phase 1
M.D. Anderson Cancer Center

2,692 total trials

What NCT05039281 shows while recruiting

NCT05039281 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 69-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (91% lower).

The record links to 2 conditions, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.

NCT05039281 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT05039281 about?

NCT05039281 is a clinical study titled "Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma". This phase I/II trial tests the safety and side effects of atezolizumab in combination with cabozantinib and whether they work to shrink tumors in patients with glioblastoma that has come back (recurrent). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune sys...

What is the current status of trial NCT05039281?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2022-09-23. Estimated completion is 2027-12-31.

What conditions does trial NCT05039281 study?

This clinical trial studies the following conditions: Recurrent Glioblastoma, Recurrent Gliosarcoma.

What interventions are being tested in trial NCT05039281?

The interventions under investigation include: Atezolizumab (BIOLOGICAL), Cabozantinib (DRUG).

Who is sponsoring clinical trial NCT05039281?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05039281 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05039281's enrollment target sits among peer trials

6 62nd of 62 higher than 1 of 62 other Recurrent Glioblastoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Recurrent Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05039281

Source: ClinicalTrials.gov NCT05039281, the US trial registry maintained by the National Library of Medicine. NCT05039281 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.